[ad_1] A doctor vaccinates an infant against respiratory syncytial virus (RSV) in a treatment room of her paediatric practice. Swen Pförtner | Picture Alliance | Getty Images The Centers for Disease Control and Prevention on Friday recommended Pfizer‘s maternal vaccine that protects infants from respiratory syncytial virus, putting the shot on track to be available in the U.S. this…
[ad_1] CFOTO | Future Publishing | Getty Images The Food and Drug Administration on Monday approved a vaccine from Pfizer that protects infants from respiratory syncytial virus, the leading cause of hospitalization among babies in the U.S. Pfizer’s RSV shot is already approved and available in the U.S. for older adults. It’s now the second…
[ad_1] A RSV-infected child receives treatment, as RS-Virus infections spread among children at Missio children’s clinic Moenchberg, in Wuerzburg, Germany, December 2, 2022. Heiko Becker | Reuters The first shot that protects all infants against respiratory syncytial virus, or RSV, won the unanimous backing of an advisory panel to the Centers for Disease Control and…
[ad_1] Packages of the weight-loss drug Wegovy from the pharmaceutical company Novo Nordisk lie on the sales counter in a Danish pharmacy. Stefan Trumpf | Picture Alliance | Getty Images U.K. health authorities on Wednesday said they are reviewing obesity and diabetes drugs like Novo Nordisk‘s Wegovy and Ozempic after some patients who took the…
[ad_1] A doctor is injecting a vaccine to a baby boy Karl Tapales | Moment | Getty Images Sanofi expects its infant RSV shot to roll out in the U.S. before respiratory virus season this fall, a company spokesperson said Friday. The Food and Drug Administration on Monday approved Beyfortus, a monoclonal antibody that is…
[ad_1] Blood sample for respiratory syncytial virus (RSV) test Jarun011 | Istock | Getty Images The Food and Drug Administration on Monday approved AstraZeneca and Sanofi‘s shot that protects infants and toddlers against respiratory syncytial virus, which is the leading cause of hospitalization among babies in the U.S. Nirsevimab is the first shot approved by…
[ad_1] An Eli Lilly and Company pharmaceutical manufacturing plant is pictured in Branchburg, New Jersey, March 5, 2021. Mike Segar | Reuters Uninsured Americans pay nearly $98 on average for a vial of Eli Lilly‘s generic insulin, even after the company pledged to cut the product’s list price to $25 per vial, according to a…
[ad_1] Nikos Pekiaridis | Nurphoto | Getty Images Moderna on Wednesday said it struck a deal with Chinese officials to research, develop and manufacture messenger RNA medicines in the country, despite rising tensions between the U.S. and China. The Massachusetts-based biotech company signed a memorandum of understanding and a related land collaboration deal to develop…
[ad_1] A panel of independent advisors to the Food and Drug Administration unanimously recommended Thursday that the antibody nirsevimab be approved for use to protect infants from respiratory syncytial virus, the leading cause of hospitalization among newborns. If the FDA approves nirsevimab, the antibody would become the first medical intervention available in the U.S. that…
[ad_1] An Eli Lilly & Co. logo is seen on a box of insulin medication in this arranged photograph at a pharmacy in Princeton, Illinois. Daniel Acker | Bloomberg | Getty Images Eli Lilly CEO Dave Ricks on Wednesday promised not to raise prices on the company’s existing insulin products again — the only executive…
